Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News VBI Vaccines Inc VBIVQ

Healthcare Biotechnology

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The... see more

Add To Watchlist

Recent & Breaking News (PINL:VBIVQ)

VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

GlobeNewswire April 19, 2018

VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

GlobeNewswire April 17, 2018

Consolidated Research: 2018 Summary Expectations for Progress Software, Cracker Barrel Old Country Store, Natural Grocers by Vitamin Cottage, VBI Vaccines, Ardelyx, and CytomX Therapeutics — Fundamental Analysis, Key Performance Indications

GlobeNewswire February 26, 2018

VBI Vaccines Announces Changes to its Board of Directors

GlobeNewswire January 26, 2018

VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901

GlobeNewswire January 17, 2018

VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine

GlobeNewswire December 19, 2017

VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

GlobeNewswire December 12, 2017

VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017

GlobeNewswire November 10, 2017

VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum

GlobeNewswire November 2, 2017

VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares

GlobeNewswire October 31, 2017

VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million

GlobeNewswire October 30, 2017

VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 Million

GlobeNewswire October 26, 2017

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares

GlobeNewswire October 25, 2017

VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017

MarketWire Canada October 17, 2017

VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona

Marketwired October 11, 2017

VBI Vaccines to Present at September 2017 Investor Conferences

MarketWire Canada September 12, 2017

VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program

MarketWire Canada August 30, 2017

VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit

MarketWire Canada August 28, 2017

VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme

MarketWire Canada August 15, 2017

VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine

MarketWire Canada July 27, 2017